$6.17
Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
Canaccord Genuity Initiates Aclaris Therapeutics at Buy With $10 Price Target
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
Overview
52-week range
$1.74
$6.60
91% of range
Avg surprise (last 3)
+11.9%
Avg reaction (last 2)
+3.2%
100% positive
Latest IV / EM
127%
EM ±19.9% · $6 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.15 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.15 | $-0.16 | +6.2% | -25.0% | +1.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.12 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.13 | $-0.13 | 0.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.12 | $-0.17 | +29.4% | — | +4.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.11 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.15 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.24 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.41 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.42 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.42 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $2M | — | $3M | $2M | $1M | — | $4M |
| Cost of revenue | $218,000 | $395,000 | — | $538,000 | $515,000 | $506,000 | — | $654,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-24M | $-22M | — | $-17M | $-18M | $-18M | — | $-10M |
| Net income | $-22M | $-20M | — | $-15M | $-15M | $-15M | — | $-8M |
| EPS (diluted) | $-0.15 | $-0.15 | — | $-0.12 | $-0.13 | $-0.12 | — | $-0.11 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19M | $29M | $20M | $25M | $25M | $30M | $25M | $48M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $98M | $110M | $96M | $101M | $104M | $109M | $126M | $132M |
| Total assets | $180M | $199M | $160M | $176M | $189M | $198M | $220M | $182M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $55M | $55M | $57M | $55M | $57M | $54M | $65M | $52M |
| Total equity | $125M | $144M | $103M | $120M | $132M | $144M | $156M | $130M |